TNXP Valuation

Tonix Pharmaceuticals Holding Corp

Add to Watchlist

Advanced Chart

17.410

-0.71(-3.918%)1D

TNXP Relative Valuation

TNXP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TNXP is overvalued; if below, it's undervalued.

Historical Valuation

Tonix Pharmaceuticals Holding Corp (TNXP) is now in the Overvalued zone, suggesting that its current forward PS ratio of 17.53 is considered Overvalued compared with the five-year average of -1.32. The fair price of Tonix Pharmaceuticals Holding Corp (TNXP) is between 2.87 to 8.92 according to relative valuation methord. Compared to the current price of 18.12 USD , Tonix Pharmaceuticals Holding Corp is Overvalued By 103.2%.

Relative Value

Fair Zone

2.87-8.92

Current Price：18.12

103.2%

Overvalued

-1.33

Trailing

Forward

0.00

EV/EBITDA

Tonix Pharmaceuticals Holding Corp. (TNXP) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -2.00. The thresholds are as follows: Strongly Undervalued below -17.50, Undervalued between -17.50 and -9.75, Fairly Valued between 5.75 and -9.75, Overvalued between 5.75 and 13.50, and Strongly Overvalued above 13.50. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.33

EV/EBIT

Tonix Pharmaceuticals Holding Corp. (TNXP) has a current EV/EBIT of -0.33. The 5-year average EV/EBIT is -0.38. The thresholds are as follows: Strongly Undervalued below -2.81, Undervalued between -2.81 and -1.59, Fairly Valued between 0.84 and -1.59, Overvalued between 0.84 and 2.06, and Strongly Overvalued above 2.06. The current Forward EV/EBIT of -0.33 falls within the Historic Trend Line -Fairly Valued range.

18.12

Tonix Pharmaceuticals Holding Corp. (TNXP) has a current PS of 18.12. The 5-year average PS is 1.72. The thresholds are as follows: Strongly Undervalued below -3.90, Undervalued between -3.90 and -1.09, Fairly Valued between 4.53 and -1.09, Overvalued between 4.53 and 7.34, and Strongly Overvalued above 7.34. The current Forward PS of 18.12 falls within the Strongly Overvalued range.

0.00

P/OCF

Tonix Pharmaceuticals Holding Corp. (TNXP) has a current P/OCF of 0.00. The 5-year average P/OCF is -2.82. The thresholds are as follows: Strongly Undervalued below -27.36, Undervalued between -27.36 and -15.09, Fairly Valued between 9.45 and -15.09, Overvalued between 9.45 and 21.72, and Strongly Overvalued above 21.72. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Tonix Pharmaceuticals Holding Corp. (TNXP) has a current P/FCF of 0.00. The 5-year average P/FCF is -1.70. The thresholds are as follows: Strongly Undervalued below -23.56, Undervalued between -23.56 and -12.63, Fairly Valued between 9.22 and -12.63, Overvalued between 9.22 and 20.15, and Strongly Overvalued above 20.15. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Tonix Pharmaceuticals Holding Corp (TNXP) has a current Price-to-Book (P/B) ratio of 0.79. Compared to its 3-year average P/B ratio of 0.40 , the current P/B ratio is approximately 98.45% higher. Relative to its 5-year average P/B ratio of 0.70, the current P/B ratio is about 12.43% higher. Tonix Pharmaceuticals Holding Corp (TNXP) has a Forward Free Cash Flow (FCF) yield of approximately -42.55%. Compared to its 3-year average FCF yield of -494.89%, the current FCF yield is approximately -91.40% lower. Relative to its 5-year average FCF yield of -351.81% , the current FCF yield is about -87.90% lower.

0.81

P/B

Median3y

0.40

Median5y

0.70

-41.17

FCF Yield

Median3y

-494.89

Median5y

-351.81

Competitors Valuation Multiple

The average P/S ratio for TNXP's competitors is 5.14, providing a benchmark for relative valuation. Tonix Pharmaceuticals Holding Corp Corp (TNXP) exhibits a P/S ratio of 18.12, which is 252.30% above the industry average. Given its robust revenue growth of -9.51%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

TNXP.O

Tonix Pharmaceuticals Holding Corp

Milestone Pharmaceuticals Inc

1.80

152.99M

ATLN.O

Atlantic International Corp

China SXT Pharmaceuticals Inc

1.66

192.61M

APLT.O

Applied Therapeutics Inc

Performance Decomposition

Market capitalization of TNXP decreased by 4.48% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -0.54 to -0.90.

The secondary factor is the Revenue Growth, contributed -9.51%to the performance.

Overall, the performance of TNXP in the past 1 year is driven by P/E Change. Which is more unsustainable.

-9.51%

2.21M → 2.00M

Revenue Growth

-60.34%

-3.57K → -1.42K

Margin Expansion

65.37%

-0.54 → -0.90

P/E Change

-4.48%